论文部分内容阅读
目的:系统评价灯盏花素注射剂联合西医常规治疗急性脑梗死(ACI)的临床疗效及安全性。方法:系统检索Embase、PubMed、the Cochrane Library、中国期刊全文数据库(CNKI)、中文科技期刊全文数据库(VIP)、中国生物医学文献数据库(SinoMed)、万方数据库1979~2016年的文献,全面搜集灯盏花素注射剂联合西医常规治疗ACI的随机对照试验,对纳入文献进行质量评价,提取资料并通过RevMan 5.3软件进行数据分析。结果:共纳入20篇文献,累计2 459例受试者。Meta分析结果显示:在常规用药的基础上,联合使用灯盏花素注射剂,临床总有效率显著提高(RR=1.28,95%CI:1.17~1.39,P<0.000 01)。此外,灯盏花素注射剂还可降低血液流变学指标,且未见严重的不良反应发生。结论:在西医常规治疗的基础上联合使用灯盏花素注射剂对ACI有较好的疗效,但其安全性仍需进一步探讨。
Objective: To systematically evaluate the clinical efficacy and safety of breviscapine injection in combination with Western routine therapy for acute cerebral infarction (ACI). Methods: The databases of Embase, PubMed, the Cochrane Library, Chinese Journal Full-text Database (CNKI), Chinese Scientific and Technical Periodicals Full Text Database (VIP), SinoMed, Wanfang Database from 1979 to 2016 were systematically searched. Breviscapine Injection and western medicine routine treatment of ACI randomized controlled trials, the inclusion of quality evaluation of the literature, data extraction and analysis by RevMan 5.3 software. Results: A total of 20 articles were included, with a total of 2 459 subjects. The results of Meta analysis showed that the combination of breviscapine injection on the basis of conventional medication significantly improved the total effective rate (RR = 1.28, 95% CI: 1.17-1.39, P <0.000 01). In addition, Breviscapine injection can also reduce hemorrheological indicators, and no serious adverse reactions occurred. Conclusion: The combination of breviscapine injection on the basis of routine treatment of Western medicine has a good effect on ACI, but its safety still needs further study.